Patients

First-in-class transformational medicines for cancer patients

We believe that cancer patients seeking clinical trials deserve experimental treatments that have transformational potential, not just incremental improvements over existing therapies. Our overarching goal is to leverage cutting-edge discoveries in how the immune system interacts with cancer cells into new medicines that act in fundamentally different ways than any other drug that has been made before.

Patients

We are proud to have advanced ST-067, an innovative experimental cancer therapy to patients in a Phase 1 safety study in the US. We are also planning additional clinical studies with ST-067 and developing new therapeutic candidates.

Phase 1a and Phase 2 Study for PK, PD, Safety and Preliminary Efficacy of ST‑067 (NCT04787042)

Intervention:

Biological: ST-067 – an engineered variant of human interleukin-18.

Trial Status:

Recruiting

Trial Information:

You can learn more about our clinical trial by clicking the ClinicalTrials.gov.

If you are a healthcare professional interested in learning more about Simcha’s current studies, please contact: info@simchatherapeutics.com